Notice of Investor Call and Presentation
Filed with ASX · · 16 pages · English
Invex Therapeutics Ltd (Invex, ASX:IXC, or the Company) a clinical-stage biopharmaceutical company focused on the development and commercialisation of Presendin™ (Exenatide) for neurological conditions relating to raised intracranial pressure (ICP), will today host an investor/analyst conference call with presentation (attached) to discuss the Collaboration and Manufacturing Agreement signed with
Invex Therapeutics Ltd. on 6ix
In the deck
Story so far
Earlier from Invex Therapeutics
- Exclusive Collaboration and Manufacturing Agreement
- Appendix 4E and Annual Report
- Invex Granted Key European Patent for Exenatide
- Invex Receives Written Response from FDA on Type C Meeting
- Invex Granted Type C Meeting with FDA
Later from Invex Therapeutics
- Global Phase 3 Trial of Presendin to Launch in Q4 2021
- Invex Therapeutics: Chairman's Address to Shareholders at AGM
- Appointment IIH EVOLVE Phase III Trial Steering Group Chair
- New Executive Director and Chairman Agreements
- Half Yearly Report and Accounts
Follow Invex Therapeutics into a list and get an email when it puts out news.
Follow Invex Therapeutics